BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 31142691)

  • 21. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triptolide inhibits the proliferation and migration of medulloblastoma Daoy cells by upregulation of microRNA-138.
    Zhang H; Li H; Liu Z; Ge A; Guo E; Liu S; Chen Z
    J Cell Biochem; 2018 Dec; 119(12):9866-9877. PubMed ID: 30156009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC.
    Chen L; Zhang Y; Tian L; Wang C; Deng T; Zheng X; Wang T; Li Z; Tang Z; Meng Q; Sun H; Li L; Ma X; Xu Y
    Eur J Med Chem; 2021 Nov; 223():113626. PubMed ID: 34218082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.
    Puglisi M; Thavasu P; Stewart A; de Bono JS; O'Brien ME; Popat S; Bhosle J; Banerji U
    Lung Cancer; 2014 Aug; 85(2):141-6. PubMed ID: 24957682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
    Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
    Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y
    Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Roles of Plant-Derived Triptolide on Non-Small Cell Lung Cancer.
    Wei J; Yan Y; Chen X; Qian L; Zeng S; Li Z; Dai S; Gong Z; Xu Z
    Oncol Res; 2019 Jul; 27(7):849-858. PubMed ID: 30982492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
    Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
    Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic antitumour effects of triptolide plus 10-hydroxycamptothecin onbladder cancer.
    Wang T; Ding Y; Yang Y; Wang Z; Gao W; Li D; Wei J; Sun Y
    Biomed Pharmacother; 2019 Jul; 115():108899. PubMed ID: 31063955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triptolide induces S phase arrest via the inhibition of cyclin E and CDC25A and triggers apoptosis via caspase- and mitochondrial-dependent signaling pathways in A375.S2 human melanoma cells.
    Hung FM; Chen YL; Huang AC; Hsiao YP; Yang JS; Chung MT; Chueh FS; Lu HF; Chung JG
    Oncol Rep; 2013 Mar; 29(3):1053-60. PubMed ID: 23314229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
    Lin Y; Yang X; Lu M; Zheng W; Zhang J; Zhuang H; Hua ZC
    Anticancer Drugs; 2013 Oct; 24(9):945-57. PubMed ID: 23958791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro.
    Biegański P; Godel M; Riganti C; Kawano DF; Kopecka J; Kowalski K
    Bioorg Chem; 2022 Feb; 119():105514. PubMed ID: 34864281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo.
    Liu Y; Xiao E; Yuan L; Li G
    DNA Cell Biol; 2014 Jul; 33(7):418-25. PubMed ID: 24720675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.